/PRNewswire/ Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations.
The news comes just six months after the Madison-based company’s last layoffs. Its revenues are growing and losses shrinking, but it’s yet to turn a profit.
ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulating tumor DNA (ctDNA) positivity and recurrence intervals MADISON, Wis., Aug. 3
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with.
Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.